---
title: "Enveric Biosciences | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295990917.md"
datetime: "2026-08-15T04:23:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295990917.md)
  - [en](https://longbridge.com/en/news/295990917.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295990917.md)
generator: "portal-rs"
---

# Enveric Biosciences | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.76.

EBIT: As of FY2026 Q2, the actual value is USD -3 M.

#### Financial Results for Second Quarter Ended June 30, 2026

-   **Net Loss Attributable to Stockholders**

    -   For the second quarter ended June 30, 2026, Enveric Biosciences, Inc. reported a net loss attributable to stockholders of - $3.0 million, which included - $0.3 million in net non-cash expense. This compares to a net loss of - $2.5 million for the quarter ended June 30, 2025, which included - $0.5 million in net non-cash expense.
-   **Basic and Diluted Loss Per Share**

    -   The basic and diluted loss per share was - $0.76 for the second quarter ended June 30, 2026. This is compared to - $11.65 for the quarter ended June 30, 2025.
-   **Cash-on-Hand**

    -   As of June 30, 2026, the Company had cash-on-hand of $8.3 million.
-   **Proceeds Raised**

    -   During the second quarter ended June 30, 2026, Enveric Biosciences, Inc. raised gross proceeds of $5.0 million through offerings. An additional $1.5 million was raised from the exercise of warrants during the same period. There is potential for up to approximately $8.9 million in additional gross proceeds if associated warrants are exercised in full.

#### Operational Highlights

-   **EB-003 Development**

    -   Enveric Biosciences, Inc. continued advancing IND-enabling studies for EB-003 and initiated genotoxicity studies, which are critical for IND submission. Preclinical data demonstrated that EB-003 consistently exhibited a non-hallucinogenic profile in a GloSensor™ assay, complementing previous BRET assay findings, and *in vitro* experiments indicated no photoreactive potential for EB-003.
-   **Intellectual Property**

    -   The Company received a Notice of Allowance from the USPTO for a patent application covering its EVM401 Series of methylone-inspired neuroplastogens. Enveric Biosciences, Inc. also secured U.S. Patent No. 12,605,361 pertaining to its EVM301 Series of molecules. A new U.S. patent covering methods of treating psychiatric disorders using compounds from Enveric’s EVM301 Series was also secured.

#### Outlook / Guidance

Enveric Biosciences, Inc.’s priorities for the second half of 2026 include completing remaining IND-enabling activities, submitting its planned Investigational New Drug (IND) application, and advancing EB-003 into a first-in-human clinical trial. The Company aims to finalize and submit its IND application to the U.S. Food and Drug Administration and receive clearance to initiate clinical trials. Enveric Biosciences, Inc. believes that recent progress has strengthened both its lead development program and its broader platform, positioning the Company to continue creating long-term strategic and shareholder value.

### Related Stocks

- [ENVB.US](https://longbridge.com/en/quote/ENVB.US.md)

## Related News & Research

- [Enveric Biosciences Q2 net loss widens](https://longbridge.com/en/news/295971436.md)
- [Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate](https://longbridge.com/en/news/294976532.md)
- [Enveric Biosciences says preclinical GloSensor assay supports non-hallucinogenic profile for EB-003](https://longbridge.com/en/news/294962761.md)
- [Enveric welcomes final FDA guidance on psychedelic drug trials](https://longbridge.com/en/news/294062160.md)
- [Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies](https://longbridge.com/en/news/285202692.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**